A panel of Aβ1‐42, t‐tau, t‐α‐syn, and o‐α‐syn together classified 64.5% of all cases correctly in the DLB, AD, PD, and control groups (lambda = 0.351, P < 0.001). This evidence concerns the gene MAPT and Alzheimer disease.